Changes in Hong Kong stocks | Rongchang Biotech (09995) rose by more than 11%, institutions say it is in the channel of commercialization capacity to accelerate cash out

The Zhitong Finance App learned that Rongchang Biotech (09995) rose by more than 11%. As of press release, it had risen 11.02% to HK$90.15, with a turnover of HK$577 million.

According to the news, according to the company's official account, the company's self-developed PD-1/VEGF bispecific antibody RC148 single-agent first-line and second-line combined treatment of non-small cell lung cancer phase I/II clinical data was announced. Research data showed that both the RC148 single drug and the combined regimen showed outstanding clinical efficacy and controllable safety, and achieved a dual-path breakthrough. Previously, the four indications of the company's two innovative drugs were successfully included in the 2025 edition of the National Medical Insurance Drug Catalogue. Zhongtai Securities previously stated that Rongchang Biotech is on the channel of accelerating the implementation of commercialization capabilities. Through efficient operation and accurate investment, the company is rapidly approaching the break-even point.

Also worth mentioning is that on December 31, 2025, CDE's official website revealed that Rongchang Biovidizumab's new indications are to be included as a breakthrough treatment, combining trastuzumab and treprilizumab for first-line treatment of advanced gastroesophageal adenocarcinoma with high HER2 expression. Previously, verdicitumab has been included in breakthrough treatment 3 times. If announced this time, it will be the 4th breakthrough treatment for this drug.